Product Information
BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE is a generic product labeled by Chartwell RX LLC, priced at $0.9482 per EA under NDC 62135043390. Its NADAC has been published 183 times since Apr 5, 2023.
FDA first approved this application on Oct 11, 1985. Its Orange Book therapeutic-equivalence code is AA.
Strength
325; 50; 40 mg/1; mg/1; mg/1
Manufacturer
Chartwell RX LLCNDC
62135043390
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ASPIRIN; BUTALBITAL; CAFFEINEApproval Type
Generic (ANDA)
FDA Application
ANDA086996FDA Approved
10/11/1985
TE Code
AA
On Market Since
10/11/1985
Pharmacological Classes
Price Statistics
The NADAC for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE has been published 183 times since Apr 5, 2023, and over the history we have for it it has risen 32.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9482 per EA |
|---|---|
| All-time high | $1.0486 (Sep 10, 2025) |
| All-time low | $0.3623 (Nov 20, 2024) |
| 52-week high | $1.0362 |
| 52-week low | $0.9482 |
| Median price | $0.8455 |
| Average price | $0.8232 |
| Largest weekly change | +59.7% (Dec 18, 2024) |
| Weeks tracked | 183 |
| Tracking since | Apr 5, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the butalbital, aspirin, and caffeine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
butalbital, aspirin, and caffeine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Barbiturate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE, manufactured by Chartwell RX LLC, is $0.9482 per EA (NDC 62135043390), effective Sep 30, 2026.
How has the price of BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE has risen 32.4%. It has been tracked across 183 weekly CMS publications since Apr 5, 2023.
What are the highest and lowest recorded NADAC prices for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE?
Since Apr 5, 2023, the NADAC for BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE has ranged from a low of $0.3623 (Nov 20, 2024) to a high of $1.0486 (Sep 10, 2025), with a median of $0.8455 per EA.
Are there cheaper alternatives to BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE?
BUTALBITAL-ASPIRIN-CAFFEINE 50-325-40 MG CAPSULE (NDC 62135043390) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.